AlphaCore Capital LLC increases its equity holdings in Johnson & Johnson (NYSE:JNJ)


AlphaCore Capital LLC increased its stake in Johnson & Johnson (NYSE: JNJ – Get Rating) by 287.6% during the first quarter, according to its latest 13F filing with the SEC. The company held 5,411 shares of the company after acquiring 4,015 additional shares during the quarter. Johnson & Johnson accounts for about 0.4% of AlphaCore Capital LLC’s portfolio, making the stock its 26th largest holding. AlphaCore Capital LLC’s holdings in Johnson & Johnson were worth $959,000 when it last filed with the SEC.

A number of other institutional investors have also recently increased or reduced their stake in the stock. Magnolia Capital Management Ltd. increased its position in Johnson & Johnson by 0.5% in the 1st quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company worth $1,978,000 after acquiring 55 additional shares during the period. Howard Financial Services LTD. strengthened its position in Johnson & Johnson by 2.1% in the 1st quarter. Howard Financial Services LTD. now owns 2,757 shares of the company worth $489,000 after acquiring 57 additional shares during the period. American Financial Advisors LLC strengthened its position in Johnson & Johnson by 2.1% in the 1st quarter. American Financial Advisors LLC now owns 2,715 shares of the company worth $481,000 after acquiring 57 additional shares during the period. Capital Investment Counsel Inc increased its position in Johnson & Johnson by 0.8% during the fourth quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company worth $1,334,000 after acquiring 59 additional shares during the period. Finally, Kwmg LLC strengthened its position in Johnson & Johnson by 2.6% in the 1st quarter. Kwmg LLC now owns 2,354 shares of the company worth $417,000 after acquiring 59 additional shares during the period. Institutional investors and hedge funds hold 68.78% of the company’s shares.

A Wall Street analyst gives his opinion

JNJ has been the subject of a number of research reports. UBS Group lowered its price target on Johnson & Johnson from $185.00 to $180.00 in a Thursday, July 21 research note. SVB Leerink lowered its price target on Johnson & Johnson from $200.00 to $194.00 in a Wednesday July 20 research note. Wells Fargo & Company raised its price target on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a Wednesday, July 13 research note. Daiwa Capital Markets launched a hedge on Johnson & Johnson in a Wednesday, June 22 research note. They issued an “outperformance” rating on the stock. Finally, Citigroup lowered its price target on Johnson & Johnson from $205.00 to $201.00 in a Wednesday, July 20 research note. Four analysts gave the stock a hold rating, five gave the company a buy rating and one gave the company’s stock a strong buy rating. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $189.89.

Insider activity

In other news, CAO Robert J. Decker sold 8,462 Johnson & Johnson shares in a trade on Thursday, May 26. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company, valued at $2,785,140. The sale was disclosed in a filing with the Securities & Exchange Commission, accessible via this link. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the company in a trade dated Thursday, May 26. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company, valued at $2,785,140. The sale was disclosed in a filing with the Securities & Exchange Commission, accessible via the SEC’s website. Additionally, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a trade dated Friday, June 10. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company, valued at approximately $12,336,803. The disclosure of this sale can be found here. 0.35% of the shares are currently held by company insiders.

Johnson & Johnson shares down 0.4%

Johnson & Johnson shares opened at $171.11 on Friday. The stock’s fifty-day moving average is $175.21 and its 200-day moving average is $174.55. The company has a market capitalization of $449.88 billion, a PE ratio of 24.91, a growth price-earnings ratio of 3.32 and a beta of 0.59. The company has a quick ratio of 1.14, a current ratio of 1.42 and a debt ratio of 0.37. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69.

Johnson & Johnson Inc (NYSE:JNJ – Get Rating) last released its quarterly results on Tuesday, July 19. The company reported earnings per share of $2.59 for the quarter, beating consensus analyst estimates of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company posted revenue of $24.02 billion for the quarter, versus a consensus estimate of $23.85 billion. In the same quarter a year earlier, the company posted earnings per share of $2.48. Johnson & Johnson’s revenue for the quarter increased 3.0% compared to the same quarter last year. Stock analysts expect Johnson & Johnson to post earnings per share of 10.05 for the current year.

Johnson & Johnson announces dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Tuesday, August 23 will receive a dividend of $1.13 per share. The ex-date of this dividend is Monday, August 22. This represents a dividend of $4.52 on an annualized basis and a dividend yield of 2.64%. Johnson & Johnson’s dividend payout ratio is 65.79%.

Johnson & Johnson Profile

(Get an assessment)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.

Read more

Want to see what other hedge funds own JNJ? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Get Rating).

Institutional ownership by quarter for Johnson & Johnson (NYSE: JNJ)



Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.

Sallie R. Loera